Article
Psychiatry
Daniel Braun, Jens Schlossmann, Ekkehard Haen
Summary: In patients with various psychiatric diseases, elevated serum concentrations of ADMA were found, suggesting its involvement in the pathophysiology of these disorders.
PSYCHIATRY RESEARCH
(2021)
Article
Clinical Neurology
Marcos Gomez-Revuelta, Jose Maria Pelayo-Teran, Javier Vazquez-Bourgon, Victor Ortiz-Garcia de la Foz, Jacqueline Mayoral-van Son, Rosa Ayesa-Arriola, Benedicto Crespo-Facorro
Summary: This study compared the effectiveness of aripiprazole and risperidone in the acute-phase treatment of FEP and found no differences in treatment discontinuation rates and mean time until discontinuation between the two drugs. However, risperidone showed better performance in terms of clinical efficacy, but patients on risperidone were more likely to experience sex-related adverse events.
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2021)
Review
Psychiatry
Li Qian, Liao Xuemei, Li Jitao, Su Yun'Ai, Si Tianmei
Summary: The high-dose treatment strategy of aripiprazole for patients with schizophrenia or schizoaffective disorder may bring more benefits without obvious side effects, as shown in a meta-analysis of nine randomized controlled trials.
FRONTIERS IN PSYCHIATRY
(2021)
Article
Health Care Sciences & Services
Stephan Reymann, Georgios Schoretsanitis, Stephan T. Egger, Alexey Mohonko, Matthias Kirschner, Stefan Vetter, Philipp Homan, Erich Seifritz, Achim Burrer
Summary: Long-acting injectable antipsychotics (LAIs) offer benefits to patients with schizophrenia spectrum disorder (SSD), but the prescription rate of LAIs in a large academic psychiatric hospital in Switzerland is relatively low. Further research will investigate the reasons for this low rate.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Multidisciplinary Sciences
Ninni Ihalainen, Eliisa Loyttyniemi, Maritta Valimaki
Summary: Self-stigma is common among people with mental disorders, especially in community settings. Having a diagnosis of an affective disorder, a long history of mental disorder, and the severity of depressive symptoms are associated with experiences of self-stigma.
Article
Clinical Neurology
Ana Monteiro Fernandes, Joao Gama Marques, Antonio Bento, Diogo Telles-Correia
Summary: The study identified the demographic profile of people living homeless with mental illness in Lisboa, Portugal, highlighting that those with multiple diagnoses have higher mental health needs and worse determinants of general health. Ongoing efforts are needed to address this subgroup to improve their treatment and outcomes.
Article
Neurosciences
Le Xiao, Qian Zhao, An-ning Li, Jushui Sun, Bin Wu, Lina Wang, Honggeng Zhang, Ruiling Zhang, Keqing Li, Xiaojin Xu, Tiebang Liu, Wenshun Zhang, Shiping Xie, Xiufeng Xu, Yunlong Tan, Kerang Zhang, Hongyan Zhang, Nianhong Guan, Mingji Xian, Motomichi Uki, Gang Wang
Summary: The study evaluated the efficacy and safety of aripiprazole once-monthly (AOM) compared to oral aripiprazole in treating acute schizophrenia. The results showed that AOM was non-inferior to oral aripiprazole in terms of efficacy and tolerability. These findings suggest that AOM could be a treatment option for patients experiencing an acute episode of schizophrenia.
PSYCHOPHARMACOLOGY
(2022)
Article
Neurosciences
Tomonari Hosokawa, Chikara Miyaji, Yusaku Yoshimura, Kenji Washida, Yuji Yada, Shinji Sakamoto, Yuko Okahisa, Soshi Takao, Akira Nomura, Yoshiki Kishi, Toshiki Harada, Manabu Takaki, Toshihiko Takeda, Norihito Yamada
Summary: This multicenter retrospective cohort study compared the continuation rates of olanzapine and aripiprazole in patients after hospital discharge at 26, 52, and 104 weeks, adjusted for possible confounders. The results showed that olanzapine had significantly higher continuation rates at 26 and 52 weeks compared to aripiprazole, but there was no significant difference at 104 weeks. Olanzapine had better efficacy, while aripiprazole had better tolerability at 104 weeks.
PSYCHOPHARMACOLOGY
(2023)
Article
Pediatrics
Takuya Saito, Yohei Hyodo, Reiko Sakaguchi, Hiroshi Nakamura, Jun Ishigooka
Summary: This study evaluated the long-term efficacy and safety of oral blonanserin in adolescents with schizophrenia. Results showed that blonanserin treatment improved or stabilized psychiatric symptoms in patients with adolescent schizophrenia, with good safety profile.
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
(2022)
Article
Clinical Neurology
Kazutaka Ohi, Kentaro Takai, Ayumi Kuramitsu, Shunsuke Sugiyama, Toshiki Shioiri
Summary: This study found that transdermal patches of blonanserin are a more effective route of administration to reduce EPS compared to oral tablets/powder.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2022)
Article
Clinical Neurology
Thanita Pilunthanakul, Mable Quek Jing Ting, Jimmy Lee, Bhanu Gupta
Summary: This study aimed to evaluate the effect of adjunctive use of aripiprazole on the QT interval of patients stabilized on atypical antipsychotics. Data from a 12-week open-label prospective trial showed that low-dose adjunctive aripiprazole did not prolong the QT interval in patients stabilized on olanzapine, risperidone, or clozapine. Further controlled studies are needed to confirm and support these findings.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
(2023)
Article
Clinical Neurology
Masaomi Iyo, Jun Ishigooka, Masatoshi Nakamura, Reiko Sakaguchi, Keisuke Okamoto, Yongcai Mao, Joyce Tsai, Alison Fitzgerald, Kentaro Takai, Teruhiko Higuchi
Summary: In this 12-week open-label extension study, lurasidone at 40 or 80 mg/day continued to be well tolerated and effective in patients with schizophrenia. Treatment-emergent adverse events were low, with akathisia being the most common. Lurasidone had minimal effects on metabolic parameters, body weight, and ECG parameters, with patients demonstrating further improvement in symptoms over the study period.
NEUROPSYCHIATRIC DISEASE AND TREATMENT
(2021)
Article
Medicine, General & Internal
Heidi C. Waters, Maelys Touya, Soon Nan Wee, Michelle Ng, Simran Thadani, Subina Surendran, Miguel Renteria, A. John Rush, Rashmi Patel, Joydeep Sarkar, Heather M. Fitzgerald, Xue Han
Summary: This retrospective observational study investigated the changes in healthcare resource utilization (HCRU) before and after the initiation of aripiprazole once-monthly (AOM 400) in patients with schizophrenia or bipolar I disorder. The study found significant improvements in hospitalization rates, emergency department visits, and average length of stay for both schizophrenia and bipolar I disorder patients after using AOM 400.
CURRENT MEDICAL RESEARCH AND OPINION
(2023)
Article
Clinical Neurology
Lucia Garrido-Sanchez, Marcos Gomez-Revuelta, Victor Ortiz-Garcia De la Foz, Jose Maria Pelayo-Teran, Maria Juncal-Ruiz, Miguel Ruiz-Veguilla, Jacqueline Mayoral-Van Son, Rosa Ayesa-Arriola, Javier Vazquez-Bourgon, Benedicto Crespo-Facorro
Summary: This study compared the short-term effectiveness of aripiprazole and risperidone in patients with first episode psychosis (FEP). The results showed no statistically significant differences in treatment discontinuation rates and time to discontinuation between the two drugs. However, aripiprazole required higher dosage and extended time to achieve clinical response.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
(2022)
Article
Health Policy & Services
Brianna Costales, Amie J. Goodin
Summary: The study found that gabapentin was widely used off-label in psychiatric patients in recent years, with a majority of patients being prescribed concomitant central nervous system depressant medications. This highlights the need for improved communication and regulation regarding medication safety.
PSYCHIATRIC SERVICES
(2021)